OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the European Patent Office has approved the Company’s patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific antigen) cancer vaccine.

The patent is broad in scope covering an array of therapeutic cancer vaccine compositions built upon OncBioMune’s protein and antigen platform technology. The patent protects OncBioMune’s PSA cancer vaccine in 38 participating European Patent Organisation states.

ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune is preparing to commence a Phase 2 trial in the U.S. evaluating ProscaVax in early-stage prostate cancer patients in the “active surveillance” category. OncBioMune and its Mexican Joint Venture partner Vitel Laboratorios S.A. de C.V. (“Vitel”) are sponsoring a Phase 2/3 clinical study of ProscaVax in Mexico evaluating the vaccine as a new treatment for recurrent prostate cancer in hormone-naïve and hormone-independent patients. As previously disclosed, OncBioMune and Vitel are working on finalizing documentation in which OncBioMune will acquire Vitel to pursue development and commercialization of drugs and drug candidates in the U.S., Latin America and worldwide.

“Our patent portfolio is now very robust, including covering ProscaVax in key markets, including the U.S., Mexico and now Europe,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Protection of intellectual property is integral to our strategy to become a global pharmaceutical brand.”

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Investor and Media Contact:

OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com